MeiraGTx Holdings plc reported cash, cash equivalents and restricted cash of $17.1 million as of September 30, 2025, compared to $105.7 million at December 31, 2024. Service revenue for the third quarter of 2025 was $0.4 million, down from $10.9 million in the same period in 2024, due to decreased activity of PPQ services under the asset purchase agreement with Johnson & Johnson Innovative Medicine. Cost of service revenue decreased to $0.3 million from $12.0 million in the prior year period. Interest income was $0.2 million, compared to $1.2 million, while interest expense was $3.1 million, down from $3.4 million. The company recorded a foreign currency loss of $1.6 million, compared to a gain of $3.5 million in the third quarter of 2024. During the quarter, MeiraGTx entered into a strategic collaboration with Eli Lilly for its AAV-AIPL1 program for Leber congenital amaurosis 4 and released material under its Specials license for a rare pediatric ophthalmology condition related to BBS10 mutations. The company expects sufficient capital to fund operations into the second half of 2027, including repayment of its $75.0 million debt due in August 2026, supported by recent and anticipated cash inflows from collaborations.